Johnson Bixby & Associates’s Pfizer PFE Stock Holding History

Johnson Bixby & Associates’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$213K	Buy	8,851 +91	+1%	+$2.38K	0.02%	124
2026 Q1	$246K	Sell	8,760 -550	-6%	-$14.6K	0.03%	116
2025 Q4	$232K	Hold	9,310	–	–	0.03%	113
2025 Q3	$237K	Sell	9,310 -550	-6%	-$13.6K	0.03%	110
2025 Q2	$239K	Sell	9,860 -25	-0.3%	-$583	0.03%	107
2025 Q1	$250K	Sell	9,885 -1,550	-14%	-$40.6K	0.04%	99
2024 Q4	$303K	Sell	11,435 -342	-3%	-$9.28K	0.05%	89
2024 Q3	$341K	Hold	11,777	–	–	0.05%	83
2024 Q2	$330K	Sell	11,777 -352	-3%	-$9.69K	0.06%	84
2024 Q1	$337K	Hold	12,129	–	–	0.06%	86
2023 Q4	$349K	Hold	12,129	–	–	0.07%	75
2023 Q3	$402K	Sell	12,129 -188	-2%	-$6.65K	0.08%	62
2023 Q2	$452K	Hold	12,317	–	–	0.09%	62
2023 Q1	$503K	Hold	12,317	–	–	0.11%	59
2022 Q4	$631K	Hold	12,317	–	–	0.15%	53
2022 Q3	$539K	Buy	12,317 +288	+2%	+$14K	0.14%	54
2022 Q2	$631K	Hold	12,029	–	–	0.15%	48
2022 Q1	$623K	Sell	12,029 -470	-4%	-$24.4K	0.16%	43
2021 Q4	$738K	Hold	12,499	–	–	0.2%	40
2021 Q3	$538K	Hold	12,499	–	–	0.16%	43
2021 Q2	$616K	Buy	12,499 +610	+5%	+$23.7K	0.18%	39
2021 Q1	$431K	Sell	11,889 -150	-1%	-$5.33K	0.14%	43
2020 Q4	$443K	Buy	+12,039	New	+$442K	0.15%	41

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Johnson Bixby & Associates's PFE Position: Q2 2026 in Review

Johnson Bixby & Associates increased its Pfizer (PFE) stake by 1% in Q2 2026, buying an estimated $2.38K and bringing the position to 8,851 shares worth $213K. The position accounts for 0.02% of the portfolio, ranked #124.

Johnson Bixby & Associates first reported a position in PFE in Q4 2020 and has held it in 23 quarters since. The position peaked at $738K in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Johnson Bixby & Associates held 8,851 shares of Pfizer worth $213K as of Q2 2026.
Johnson Bixby & Associates bought 91 Pfizer shares in Q2 2026, an estimated $2.38K.
Pfizer made up 0.02% of Johnson Bixby & Associates's portfolio in Q2 2026, its #124 holding.
Johnson Bixby & Associates first reported a position in Pfizer in Q4 2020 and has held it in 23 quarters since.
Johnson Bixby & Associates's Pfizer position peaked at $738K in Q4 2021.
2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Johnson Bixby & Associates's 13F filing for Q2 2026, filed 16 Jul 2026.